Why Do Phase III Clinical Trials in Oncology Fail so Often?

被引：40
作者：
Amiri-Kordestani, Laleh [1 ]
Fojo, Tito [1 ]
机构：
[1] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2012年 / 104卷 / 08期
关键词：
DRUG DEVELOPMENT; TARGETED AGENTS; STABLE DISEASE; END-POINT; CHEMOTHERAPY; SURVIVAL; CANCER; BENEFIT; DESIGNS;
D O I：
10.1093/jnci/djs180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：568 / 569
页数：2
相关论文
共 50 条
[21]   Phase II clinical trials in oncology: are we hitting the target? [J].
Ang, Mei-Kim ;
Tan, Say-Beng ;
Lim, Wan-Teck .
EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (03) :427-438
[22]   Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials [J].
van der Biessen, Diane A. J. ;
Cranendonk, Merlijn A. ;
Schiavon, Gaia ;
van der Holt, Bronno ;
Wiemer, Erik A. C. ;
Eskens, Ferry A. L. M. ;
Verweij, Jaap ;
de Jonge, Maja J. A. ;
Mathijssen, Ron H. J. .
ONCOLOGIST, 2013, 18 (03) :323-329
[23]   A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology [J].
Comets, Emmanuelle ;
Zohar, Sarah .
CLINICAL PHARMACOKINETICS, 2009, 48 (06) :387-395
[24]   Phase III clinical trials with darbepoetin: implications for clinicians [J].
Glaspy, J .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (03) :407-416
[25]   Optimal planning of phase II/III programs for clinical trials with multiple endpoints [J].
Kieser, Meinhard ;
Kirchner, Marietta ;
Doelger, Eva ;
Goette, Heiko .
PHARMACEUTICAL STATISTICS, 2018, 17 (05) :437-457
[26]   Survival-inferred fragility of statistical significance in phase III oncology trials [J].
Sherry, Alexander D. ;
Liu, Yufei ;
Msaouel, Pavlos ;
Lin, Timothy A. ;
Koong, Alex ;
Lin, Christine ;
Abi Jaoude, Joseph ;
Patel, Roshal R. ;
Kouzy, Ramez ;
El-Alam, Molly B. ;
Miller, Avital M. ;
Owiwi, Mohannad ;
Ofer, Jonathan ;
Bomze, David ;
Mccaw, Zachary R. ;
Meirson, Tomer ;
Ludmir, Ethan B. .
NPJ PRECISION ONCOLOGY, 2025, 9 (01)
[27]   Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review [J].
Bregni, Giacomo ;
Trevisi, Elena ;
Conde, Rita Saude ;
Vanhooren, Michele ;
Telli, Tugba Akin ;
Assaf, Irene ;
Hendlisz, Alain ;
Di Maio, Massimo ;
Sclafani, Francesco .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (05) :505-513
[28]   Do investigators show selection biases when enrolling patients in phase I oncology registration trials? [J].
Yonemori, Kan ;
Hirakawa, Akihiro ;
Ando, Masashi ;
Hirata, Taizo ;
Shimizu, Chikako ;
Katsumata, Noriyuki ;
Tamura, Kenji ;
Fujiwara, Yasuhiro .
JOURNAL OF GERIATRIC ONCOLOGY, 2011, 2 (01) :25-30
[29]   Why performance status? A case for alternative functional assessments in pediatric oncology clinical trials [J].
Steineck, Angela ;
Rosenberg, Abby R. .
CANCER, 2021, 127 (19) :3511-3513
[30]   Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II? [J].
O'Donnell, Peter H. ;
Stadler, Walter M. .
CLINICAL CANCER RESEARCH, 2012, 18 (10) :2809-2816
12345